Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole

Jacqueline M. Dempsey, Kelley M. Kidwell, Christina L. Gersch, Andrea M. Pesch, Zeruesenay Desta, Anna Maria Storniolo, Vered Stearns, Todd Skaar, Daniel F. Hayes, N. Lynn Henry, James M. Rae, Daniel L. Hertz

Research output: Contribution to journalArticle

Abstract

Aim: This study tested for associations between SLCO1B1 polymorphisms and circulating estrogen levels in women with breast cancer treated with letrozole or exemestane. Patients & methods: Postmenopausal women with hormone-receptor positive breast cancer were genotyped for SLCO1B1∗5 (rs4149056) and rs10841753. Pretreatment and on-treatment plasma estrogens and aromatase inhibitor (AI) concentrations were measured. Regression analyses were performed to test for pharmacogenetic associations with estrogens and drug concentrations. Results: SLCO1B1∗5 was associated with elevated pretreatment estrone sulfate and an increased risk of detectable estrone concentrations after 3 months of AI treatment. Conclusion: These findings suggest SLCO1B1 polymorphisms may have an effect on estrogenic response to AI treatment, and therefore may adversely impact the anticancer effectiveness of these agents.

Original languageEnglish (US)
Pages (from-to)571-580
Number of pages10
JournalPharmacogenomics
Volume20
Issue number8
DOIs
StatePublished - Jan 1 2019

Fingerprint

exemestane
letrozole
Aromatase Inhibitors
Estrogens
Breast Neoplasms
Estrone
Pharmacogenetics
Antineoplastic Agents
Therapeutics
Regression Analysis
Hormones
Pharmaceutical Preparations

Keywords

  • breast cancer
  • exemestane
  • letrozole
  • pharmacogenomics
  • SLCO1B1

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Cite this

Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole. / Dempsey, Jacqueline M.; Kidwell, Kelley M.; Gersch, Christina L.; Pesch, Andrea M.; Desta, Zeruesenay; Storniolo, Anna Maria; Stearns, Vered; Skaar, Todd; Hayes, Daniel F.; Henry, N. Lynn; Rae, James M.; Hertz, Daniel L.

In: Pharmacogenomics, Vol. 20, No. 8, 01.01.2019, p. 571-580.

Research output: Contribution to journalArticle

Dempsey, Jacqueline M. ; Kidwell, Kelley M. ; Gersch, Christina L. ; Pesch, Andrea M. ; Desta, Zeruesenay ; Storniolo, Anna Maria ; Stearns, Vered ; Skaar, Todd ; Hayes, Daniel F. ; Henry, N. Lynn ; Rae, James M. ; Hertz, Daniel L. / Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole. In: Pharmacogenomics. 2019 ; Vol. 20, No. 8. pp. 571-580.
@article{4c77a93474ff4336a1f1b6f4763a5c8a,
title = "Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole",
abstract = "Aim: This study tested for associations between SLCO1B1 polymorphisms and circulating estrogen levels in women with breast cancer treated with letrozole or exemestane. Patients & methods: Postmenopausal women with hormone-receptor positive breast cancer were genotyped for SLCO1B1∗5 (rs4149056) and rs10841753. Pretreatment and on-treatment plasma estrogens and aromatase inhibitor (AI) concentrations were measured. Regression analyses were performed to test for pharmacogenetic associations with estrogens and drug concentrations. Results: SLCO1B1∗5 was associated with elevated pretreatment estrone sulfate and an increased risk of detectable estrone concentrations after 3 months of AI treatment. Conclusion: These findings suggest SLCO1B1 polymorphisms may have an effect on estrogenic response to AI treatment, and therefore may adversely impact the anticancer effectiveness of these agents.",
keywords = "breast cancer, exemestane, letrozole, pharmacogenomics, SLCO1B1",
author = "Dempsey, {Jacqueline M.} and Kidwell, {Kelley M.} and Gersch, {Christina L.} and Pesch, {Andrea M.} and Zeruesenay Desta and Storniolo, {Anna Maria} and Vered Stearns and Todd Skaar and Hayes, {Daniel F.} and Henry, {N. Lynn} and Rae, {James M.} and Hertz, {Daniel L.}",
year = "2019",
month = "1",
day = "1",
doi = "10.2217/pgs-2019-0020",
language = "English (US)",
volume = "20",
pages = "571--580",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "8",

}

TY - JOUR

T1 - Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole

AU - Dempsey, Jacqueline M.

AU - Kidwell, Kelley M.

AU - Gersch, Christina L.

AU - Pesch, Andrea M.

AU - Desta, Zeruesenay

AU - Storniolo, Anna Maria

AU - Stearns, Vered

AU - Skaar, Todd

AU - Hayes, Daniel F.

AU - Henry, N. Lynn

AU - Rae, James M.

AU - Hertz, Daniel L.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Aim: This study tested for associations between SLCO1B1 polymorphisms and circulating estrogen levels in women with breast cancer treated with letrozole or exemestane. Patients & methods: Postmenopausal women with hormone-receptor positive breast cancer were genotyped for SLCO1B1∗5 (rs4149056) and rs10841753. Pretreatment and on-treatment plasma estrogens and aromatase inhibitor (AI) concentrations were measured. Regression analyses were performed to test for pharmacogenetic associations with estrogens and drug concentrations. Results: SLCO1B1∗5 was associated with elevated pretreatment estrone sulfate and an increased risk of detectable estrone concentrations after 3 months of AI treatment. Conclusion: These findings suggest SLCO1B1 polymorphisms may have an effect on estrogenic response to AI treatment, and therefore may adversely impact the anticancer effectiveness of these agents.

AB - Aim: This study tested for associations between SLCO1B1 polymorphisms and circulating estrogen levels in women with breast cancer treated with letrozole or exemestane. Patients & methods: Postmenopausal women with hormone-receptor positive breast cancer were genotyped for SLCO1B1∗5 (rs4149056) and rs10841753. Pretreatment and on-treatment plasma estrogens and aromatase inhibitor (AI) concentrations were measured. Regression analyses were performed to test for pharmacogenetic associations with estrogens and drug concentrations. Results: SLCO1B1∗5 was associated with elevated pretreatment estrone sulfate and an increased risk of detectable estrone concentrations after 3 months of AI treatment. Conclusion: These findings suggest SLCO1B1 polymorphisms may have an effect on estrogenic response to AI treatment, and therefore may adversely impact the anticancer effectiveness of these agents.

KW - breast cancer

KW - exemestane

KW - letrozole

KW - pharmacogenomics

KW - SLCO1B1

UR - http://www.scopus.com/inward/record.url?scp=85067288589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067288589&partnerID=8YFLogxK

U2 - 10.2217/pgs-2019-0020

DO - 10.2217/pgs-2019-0020

M3 - Article

VL - 20

SP - 571

EP - 580

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 8

ER -